A Study of Lebrikizumab (LY3650150) in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Previously Treated With Dupilumab

NCT05369403 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

Atopic Dermatitis

Interventions

DRUG: Lebrikizumab

Sponsor

Eli Lilly and Company